Half-life extension via ADB-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.
Zhang J, Bodenko V, Larkina M, Bezverkhniaia E, Xu T, Liao Y, Abouzayed A, Plotnikov E, Tretyakova M, Yuldasheva F, Belousov MV, Orlova A, Tolmachev V, Gräslund T, Vorobyeva A.
Zhang J, et al. Among authors: xu t.
J Control Release. 2024 Apr 30:S0168-3659(24)00280-3. doi: 10.1016/j.jconrel.2024.04.051. Online ahead of print.
J Control Release. 2024.
PMID: 38697314